Cargando…

Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients

INTRODUCTION: This study reports the long-term intraocular pressure (IOP)-lowering efficacy and safety of a single trabecular microbypass stent (iStent(®); Glaukos Corp., San Clemente, CA, USA) for medically controlled open-angle glaucoma in Korean patients. METHODS: This retrospective observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Myungjin, Rho, Seungsoo, Lim, Su-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640437/
https://www.ncbi.nlm.nih.gov/pubmed/37792244
http://dx.doi.org/10.1007/s40123-023-00824-8
_version_ 1785146631726825472
author Kim, Myungjin
Rho, Seungsoo
Lim, Su-Ho
author_facet Kim, Myungjin
Rho, Seungsoo
Lim, Su-Ho
author_sort Kim, Myungjin
collection PubMed
description INTRODUCTION: This study reports the long-term intraocular pressure (IOP)-lowering efficacy and safety of a single trabecular microbypass stent (iStent(®); Glaukos Corp., San Clemente, CA, USA) for medically controlled open-angle glaucoma in Korean patients. METHODS: This retrospective observational study included 42 eyes of 35 patients with primary open-angle glaucoma (POAG). All subjects underwent single first-generation iStent(®) implantation with phacoemulsification by a single surgeon with 5 years follow-up. The primary outcomes were changes in IOP and the number of antiglaucoma medications compared to the preoperative values. The secondary outcome was the proportion of eyes with IOP ≤ 18 mmHg without medication, ≤ 15 mmHg without medication, and ≤ 18 mmHg with or without medication. Adverse events and need for secondary glaucoma surgery were also recorded. RESULTS: The mean IOP decreased from 15.8 ± 2.8 to 13.8 ± 1.7 mmHg and the mean number of medications was reduced from 2.24 ± 1.18 to 0.83 ± 1.12, respectively, at year 5. At 3 and 5 years, 80.6% and 78.6% of eyes, respectively, were receiving fewer medications than preoperative numbers. In contrast, only 50% of eyes on four preoperative medications showed medication reductions at 5 years. At years 3 and 5, 61.3% and 53.5% of eyes achieved IOP ≤ 18 mmHg without medication, whereas 90.3% and 89.3% of eyes achieved ≤ 18 mmHg regardless of medication use, respectively. Four eyes required additional glaucoma surgery (two Ahmed glaucoma valve implantations, one trabeculectomy, and one XEN 45 Gel Stent implantation), and all were receiving four preoperative antiglaucoma medications. Transient IOP elevation (14.3%) was the most common complication, followed by five hyphema, one stent obstruction, one stent malposition, and one severe anterior chamber reaction. CONCLUSION: This study demonstrated a good safety profile and sustained IOP reduction after the implantation of a single trabecular microbypass stent (iStent(®)) with phacoemulsification in Korean patients. The majority of subjects with POAG showed a relatively good response; however, eyes receiving a higher number of medications preoperatively (especially four medications) had difficulty achieving a low target IOP.
format Online
Article
Text
id pubmed-10640437
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-106404372023-11-15 Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients Kim, Myungjin Rho, Seungsoo Lim, Su-Ho Ophthalmol Ther Original Research INTRODUCTION: This study reports the long-term intraocular pressure (IOP)-lowering efficacy and safety of a single trabecular microbypass stent (iStent(®); Glaukos Corp., San Clemente, CA, USA) for medically controlled open-angle glaucoma in Korean patients. METHODS: This retrospective observational study included 42 eyes of 35 patients with primary open-angle glaucoma (POAG). All subjects underwent single first-generation iStent(®) implantation with phacoemulsification by a single surgeon with 5 years follow-up. The primary outcomes were changes in IOP and the number of antiglaucoma medications compared to the preoperative values. The secondary outcome was the proportion of eyes with IOP ≤ 18 mmHg without medication, ≤ 15 mmHg without medication, and ≤ 18 mmHg with or without medication. Adverse events and need for secondary glaucoma surgery were also recorded. RESULTS: The mean IOP decreased from 15.8 ± 2.8 to 13.8 ± 1.7 mmHg and the mean number of medications was reduced from 2.24 ± 1.18 to 0.83 ± 1.12, respectively, at year 5. At 3 and 5 years, 80.6% and 78.6% of eyes, respectively, were receiving fewer medications than preoperative numbers. In contrast, only 50% of eyes on four preoperative medications showed medication reductions at 5 years. At years 3 and 5, 61.3% and 53.5% of eyes achieved IOP ≤ 18 mmHg without medication, whereas 90.3% and 89.3% of eyes achieved ≤ 18 mmHg regardless of medication use, respectively. Four eyes required additional glaucoma surgery (two Ahmed glaucoma valve implantations, one trabeculectomy, and one XEN 45 Gel Stent implantation), and all were receiving four preoperative antiglaucoma medications. Transient IOP elevation (14.3%) was the most common complication, followed by five hyphema, one stent obstruction, one stent malposition, and one severe anterior chamber reaction. CONCLUSION: This study demonstrated a good safety profile and sustained IOP reduction after the implantation of a single trabecular microbypass stent (iStent(®)) with phacoemulsification in Korean patients. The majority of subjects with POAG showed a relatively good response; however, eyes receiving a higher number of medications preoperatively (especially four medications) had difficulty achieving a low target IOP. Springer Healthcare 2023-10-04 2023-12 /pmc/articles/PMC10640437/ /pubmed/37792244 http://dx.doi.org/10.1007/s40123-023-00824-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Kim, Myungjin
Rho, Seungsoo
Lim, Su-Ho
Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients
title Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients
title_full Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients
title_fullStr Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients
title_full_unstemmed Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients
title_short Five-Year Outcomes of Single Trabecular Microbypass Stent (iStent(®)) Implantation with Phacoemulsification in Korean Patients
title_sort five-year outcomes of single trabecular microbypass stent (istent(®)) implantation with phacoemulsification in korean patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640437/
https://www.ncbi.nlm.nih.gov/pubmed/37792244
http://dx.doi.org/10.1007/s40123-023-00824-8
work_keys_str_mv AT kimmyungjin fiveyearoutcomesofsingletrabecularmicrobypassstentistentimplantationwithphacoemulsificationinkoreanpatients
AT rhoseungsoo fiveyearoutcomesofsingletrabecularmicrobypassstentistentimplantationwithphacoemulsificationinkoreanpatients
AT limsuho fiveyearoutcomesofsingletrabecularmicrobypassstentistentimplantationwithphacoemulsificationinkoreanpatients